ProCE Banner Activity

LIBRETTO-431: Randomized Phase III Trial of First-line Selpercatinib vs Chemotherapy Plus Pembrolizumab in RET Fusion‒Positive NSCLC

Conference Coverage

In the phase III LIBRETTO-431 trial, first-line selpercatinib significantly improved median PFS vs chemotherapy plus pembrolizumab (HR: 0.465), meeting the primary endpoint and supporting selpercatinib as a standard of care for patients with RET fusion‒positive NSCLC.

Released: October 24, 2023


Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner


Supported by educational grants from AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Inc., Exelixis, Inc., Gilead Sciences, Inc., Lilly and Regeneron Pharmaceuticals, Inc.


Bristol Myers Squibb

Daiichi Sankyo, Inc.

Exelixis, Inc.

Gilead Sciences, Inc.


Regeneron Pharmaceuticals, Inc